Cellular immune response in HCV infection

Journal of Gastroenterology

Volumn 35, Issue 12, 2000, Pages 881-889

  Nakamura I, ^a   Imawari, M ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

CTL; HCV; Helper T Cell; Immune response

Indexed keywords

ALPHA INTERFERON; AMINO ACID DERIVATIVE; BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; CELL SURFACE PROTEIN; CORE PROTEIN; DNA VACCINE; FAS ANTIGEN; FAS LIGAND; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; PERFORIN; STRUCTURAL PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; CHIMPANZEE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG ACTIVITY; ERADICATION THERAPY; HEPATITIS C; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOMODULATION; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT PLASMID; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS HEPATITIS; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERFERON-ALPHA; INTERFERON-BETA; INTERLEUKIN-12; MICE; MICE, TRANSGENIC; RECEPTORS, INTERLEUKIN-4; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034518533     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350070001     Document Type: Review

References (87)

1. Hepatitis C and hepatocellular carcinoma
2. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
3. Clinical outcomes after transfusion-associated hepatitis C
4. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: Implications for vaccine development
5. Lymphocyte granule-mediated apoptosis: Matters of viral mimicry and deadly proteases
6. Entry and trafficking of granzyme B in target cells during granzyme B-perforin-mediated apoptosis
7. How do cytotoxic lymphocytes kill their targets?
8. Granzyme A initiates an alternative pathway for granule-mediated apoptosis
9. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
10. The pathophysiology of tumor necrosis factors
11. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL
12. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C
13. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections
14. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
15. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
16. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection
17. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection
18. Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection
19. T-Cell mechanisms in the immunopathogenesis of viral hepatitis B and C
20. The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome
21. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C
22. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients
23. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C
24. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa
25. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation
26. A helper T-cell antigen enhances generation of hepatitis C virus cytotoxic T lymphocytes in vitro
27. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice
28. Viral clearance without destruction of infected cells during acute HBV infection
29. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte
30. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis
31. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV
32. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release
33. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection
34. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans
35. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1
36. Cytotoxic T lymphocyte response to hepatitis C-derived peptides containing the HLA A2.1 motif
37. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules
38. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein
39. Recognition of hepatitis C virus nucleocapsid protein-derived peptides by cytotoxic T lymphocytes
40. HLA B44-restricted cytotoxic T lymphocyte responses to the peptides of HCV nucleoprotein residues 81-100 in patients with chronic hepatitis C
41. A minimal and optimal cytotoxic T-cell epitope within hepatitis C virus nucleoprotein
42. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C
43. Three new cytotoxic T cell epitopes identified within the hepatitis C virus nucleoprotein
44. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection
45. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers
46. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients
47. Analysis of a successful immune response against hepatitis C virus
48. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies
49. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
50. Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway
51. Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection
52. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection
53. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein
54. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity
55. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus
56. Suppression of host immune response by the core protein of hepatitis C virus: Possible implications for hepatitis C virus persistence
57. Prometheus through the looking glass: Reflections on the hepatic immune system
58. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals
59. Low stimulatory capacity of lymphoid dendritic cells expressing hepatitis C virus genes
60. Inhibition of the interferon-inducible protein kinase PKR by HCV E2
61. Effect of immune globulin on the prevention of experimental hepatitis C virus infection
62. Anti-hepatitis C antibodies in patients with chronic non-A, non-B hepatitis: Relation to disease progression and effect of interferon alpha
63. Lack of protective immunity against reinfection with hepatitis C virus
64. Immunity in chimpanzees chronically infected with hepatitis C virus: Role of minor quasispecies in reinfection
65. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis
66. Role of Fas ligand in apoptosis induced by hepatitis C virus infection
67. Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis
68. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease
69. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia
70. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders
71. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection
72. Clinical hepatitis after transplantation of hepatitis C virus-positive kidneys: HLA-DR3 as a risk factor for the development of posttransplant hepatitis
73. Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in northern European caucasoids
74. Association between MHC class II alleles and clearance of circulating hepatitis C virus
75. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C
76. Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin
77. Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation
78. Analysis of HLA alleles in Japanese patients with cirrhosis due to chronic hepatitis C
79. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus
80. HLA class II favors clearance of HCV infection and progression of the chronic liver damage
81. Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection
82. Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome
83. The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C
84. Possible association between HLA antigens and the response to interferon in Japanese patients with chronic hepatitis C
85. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination
86. Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization
87. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans